Insider Selling: Keros Therapeutics, Inc. (NASDAQ:KROS) Director Sells 27,151 Shares of Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) Director Julius Knowles sold 27,151 shares of the firm’s stock in a transaction on Monday, April 5th. The stock was sold at an average price of $60.07, for a total value of $1,630,960.57. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Julius Knowles also recently made the following trade(s):

  • On Thursday, April 1st, Julius Knowles sold 11,202 shares of Keros Therapeutics stock. The shares were sold at an average price of $58.89, for a total value of $659,685.78.
  • On Wednesday, March 3rd, Julius Knowles sold 12,327 shares of Keros Therapeutics stock. The stock was sold at an average price of $57.36, for a total value of $707,076.72.
  • On Monday, March 1st, Julius Knowles sold 12,979 shares of Keros Therapeutics stock. The shares were sold at an average price of $63.09, for a total value of $818,845.11.
  • On Thursday, February 18th, Julius Knowles sold 28,617 shares of Keros Therapeutics stock. The stock was sold at an average price of $60.87, for a total transaction of $1,741,916.79.
  • On Thursday, February 11th, Julius Knowles sold 11,561 shares of Keros Therapeutics stock. The shares were sold at an average price of $64.82, for a total transaction of $749,384.02.

Shares of NASDAQ KROS opened at $61.01 on Thursday. The firm has a fifty day simple moving average of $60.73 and a 200 day simple moving average of $62.19. Keros Therapeutics, Inc. has a twelve month low of $19.10 and a twelve month high of $88.80.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, March 24th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.08. On average, research analysts predict that Keros Therapeutics, Inc. will post -4.14 EPS for the current fiscal year.

Large investors have recently added to or reduced their stakes in the company. Logos Global Management LP lifted its position in shares of Keros Therapeutics by 300.0% during the 3rd quarter. Logos Global Management LP now owns 1,600,000 shares of the company’s stock valued at $61,712,000 after acquiring an additional 1,200,000 shares during the period. BlackRock Inc. increased its stake in Keros Therapeutics by 83.2% in the fourth quarter. BlackRock Inc. now owns 1,199,201 shares of the company’s stock valued at $84,590,000 after purchasing an additional 544,559 shares in the last quarter. Caas Capital Management LP acquired a new position in shares of Keros Therapeutics during the fourth quarter valued at about $6,440,000. Morgan Stanley boosted its position in shares of Keros Therapeutics by 11,963.0% during the 4th quarter. Morgan Stanley now owns 75,635 shares of the company’s stock worth $5,336,000 after purchasing an additional 75,008 shares in the last quarter. Finally, Nuveen Asset Management LLC grew its stake in shares of Keros Therapeutics by 250.8% in the 4th quarter. Nuveen Asset Management LLC now owns 95,012 shares of the company’s stock valued at $6,702,000 after buying an additional 67,928 shares during the period. Institutional investors own 58.38% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Recommended Story: What is a SEC Filing?

Insider Buying and Selling by Quarter for Keros Therapeutics (NASDAQ:KROS)

Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.